



EXPRESS SCRIPTS®

**Express Scripts, Inc.
Pharmacy and Therapeutics Committee
Proceedings
December 3, 2009**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. Berinert® (C1 esterase inhibitor [human] for intravenous use [freeze dried powder for reconstitution]) - CSL Behring**
- B. Cervarix® (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant injection) – GlaxoSmithKline**
- C. Votrient™ (pazopanib tablets) - GlaxoSmithKline**

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. Abilify® (aripiprazole tablets, orally disintegrating tablets, and oral solution) - Bristol-Myers Squibb** - For the treatment of irritability associated with autistic disorder in pediatric patients (aged 6 to 17 years).
- B. Atacand® (candesartan cilexetil tablets) AstraZeneca** - For the treatment of hypertension, alone or in combination with other antihypertensive agents, in children 1 to less than 17 years of age.
- C. Byetta® (exenatide injection) - Amylin Pharmaceuticals** - As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- D. Colcrys™ (colchicine tablets) - Mutual Pharmaceutical Company, Inc.** - For prophylaxis of gout flares.
- E. Crestor® (rosuvastatin calcium tablets) - AstraZeneca** - As an adjunct to diet to reduce total cholesterol, low density lipoprotein (LDL-C), and ApoB levels in adolescent boys and girls, who are at least one year post-menarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C > 190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors.
- F. Gardasil® (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant) - Merck** - Prevention of genital warts (condyloma acuminata) caused by human papillomavirus (HPV) types 6 and 11 in boys and men 9 through 26 years of age.
- G. Geodon® (ziprasidone capsules) - Pfizer** - For maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or valproate.
- H. Locoid Lipocream® (hydrocortisone butyrate 0.1% cream) - Triax Pharmaceuticals** – For the topical treatment of mild to moderate atopic dermatitis in pediatric patients 3 months to 18 years of age.
- I. Micardis® (telmisartan tablets) - Boehringer Ingelheim** - For reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin converting enzyme (ACE) inhibitors.

- J. Rebetol® (ribavirin capsules and oral solution) - Schering Plough** - For the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease in combination with interferon alfa-2b (pegylated and nonpegylated).

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions.

- A. Fibracor™ (fenofibric acid tablets) - Mutual Pharmaceutical Co.**
B. Twynsta® (telmisartan/ amlodipine tablets) - Boehringer Ingelheim